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Background: Human and animal studies have shown associations between insulin growth factor 2 (IGF2) and diabetes.
Results: Overexpression of insulin growth factor 2 in -cells leads to -cell dysfunction and makes islets more vulnerable to
-cell damage and immune attack.
Conclusion: IGF2 may play an important role in the predisposition and development of diabetes.
Significance: This study unravels an unprecedented role of IGF2 on physiology of -cells.
The human insulin-like growth factor 2 (IGF2) and insulin
genes are located within the same genomic region. Although
human genomic studies have demonstrated associations be-
tween diabetes and the insulin/IGF2 locus or the IGF2
mRNA-binding protein 2 (IGF2BP2), the role of IGF2 in diabe-
tes pathogenesis is not fully understood. We previously
described that transgenicmice overexpressing IGF2 specifically
in-cells (Tg-IGF2) develop a pre-diabetic state. Here, we char-
acterized the effects of IGF2 on -cell functionality. Overex-
pressionof IGF2 led to-cell dedifferentiation andendoplasmic
reticulum stress causing islet dysfunction in vivo. Both adenovi-
rus-mediated overexpression of IGF2 and treatment of adult
wild-type islets with recombinant IGF2 in vitro further con-
firmed the direct implication of IGF2 on -cell dysfunction.
Treatment of Tg-IGF2 mice with subdiabetogenic doses of
streptozotocin or crossing these mice with a transgenic model
of islet lymphocytic infiltration promoted the development of
overt diabetes, suggesting that IGF2 makes islets more suscep-
tible to -cell damage and immune attack. These results indi-
cate that increased local levels of IGF2 in pancreatic islets may
predispose to the onset of diabetes. This study unravels an
unprecedented role of IGF2 on -cells function.
-Cell dysfunction and reductions in -cell mass are patho-
logical alterations central to the development of both type 1
(T1D)6 and type 2 diabetes (T2D) (1). In particular, T2D may
begin with insulin resistance, but overt T2D only develops
when -cells fail to compensate for the increased insulin
demand. Thus, the alteration in the function of-cells would be
a primary defect in the pathogenesis of diabetes (2).
The concept of loss of -cell differentiation was first intro-
duced by Jonas et al. (3) in 1999 to describe a change in the
phenotype of -cells by which functions of the fully differenti-
ated cells necessary for optimal functioning, such as insulin
secretion, are lost (4). The progressive changes in -cell pheno-
types observed during dedifferentiation include the down-reg-
ulation of many genes that are highly expressed in -cells, e.g.
insulin (INS), solute carrier family member 2 (SLC2A2 or
GLUT2), glucokinase (GCK), and pancreatic and duodenal
homeobox 1 (PDX1) (5). The term dedifferentiation has been
used, for example, to describe the phenotype observed in
knock-outmice for the transcription factorFoxo1 specifically in
-cells. In this animal model that develops overt hyperglyce-
mia,-cells were described to have dedifferentiated to a state of
immaturity characterized by positivity for markers of multipo-
tency and plasticity and for markers of endocrine progenitor
cells and by lack the of insulin production (6). Other authors
have also used the term dedifferentiation to describe the loss of
-cell identity due to the inactivation of transcription factors
that define -cell fate (7, 8). Importantly, recent evidence attri-
butes to dedifferentiation of -cells a causative role in -cell
failure in T2D (6, 9, 10).
In parallel to-cell dedifferentiation,many animalmodels of
T1D also show endoplasmic reticulum (ER) stress. Given that
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-cells need to produce insulin in large quantities, they proba-
bly represent a cell type vulnerable to ER stress (11). In fact, ER
stress has been proposed as a mechanism responsible for -cell
dysfunction and death in type 2 diabetes (12), and it has been
reported to precede the onset of T1D in the nonobese diabetic
mouse model (13). The major indicators of the ER stress
response, such as X-box binding protein 1 (Xbp1) and DNA-
damage inducible transcript 3 (Ddit3/Chop), are up-regulated
in islets from type 1 and type 2 diabetic models (12, 14, 15).
Insulin-like growth factor 2 (IGF2) is a growth-promoting
polypeptide that shares a high degree of structural homology
with insulin. IGF2 is synthesized primarily by the liver, but it is
also produced locally by many tissues, where it acts in an auto-
crine/paracrine manner (16). IGF2 is expressed at high levels
during embryonic development, but its expression is progres-
sively shut down in most tissues after birth. In humans, the
IGF2 gene is located on chromosome 11p15.5, in close linkage
with the INS and tyrosine hydroxylase (TH) genes. Because the
IGF2 and INS genes share their promoter, the human pancreas
can express INS-IGF2hybrid transcripts (17). Indeed, in human
-cells insulin is the most abundant transcript, followed by
INS-IGF2 hybrids and IGF2 transcripts (18). Genome-wide
association studies performed in humans from Caucasian and
Asian populations have demonstrated associations between the
IDDM2 locus containing the INS and IGF2 genes and diabetes
(19). In particular, variations in the size and sequence of a reg-
ulatory element of the insulin promoter that includes a variable
number of tandem repeats (VNTR) have been found to confer
susceptibility to T1D (the shortest version of VNTR or class I)
or to T2D (the longest version of VNTR or class III) (20, 21).
Pugliese et al. (20) suggested that although there is clear evi-
dence supporting the concept that the INS VNTR element is
the main factor conferring susceptibility to diabetes to the
IDDM2 locus, there is also the possibility that, at least in some
instances, both the INS and IGF2 locus modulate IDDM2-con-
ferred susceptibility. In contrast, the IGF2BP2 (IMP2) gene,
involved in the regulation of IGF2 expression by binding to the
5-UTR of the IGF2mRNA to promote its translation (22), has
also been associatedwith genome-wide association studieswith
an increased risk of T2D and gestational diabetes in Caucasian,
Asian, and Arabic populations (23–25). IGF2BP2 is expressed
in -cells and in insulin-sensitive tissues in postnatal life (22),
and an altered expression or regulation of the IGF2BP2 gene
may end up impacting the levels of IGF2 in these cells. Further-
more, old Goto-Kakizaki rats, a nonobese model of mild T2D,
show increased IGF2mRNA in their islets (26).
We previously showed that transgenic mice overexpressing
IGF2 specifically in -cells (Tg-IGF2) display several primary
defects characteristic of T2D, such as hyperinsulinemia, mild
hyperglycemia, and altered glucose and insulin tolerance tests
(27). These observations together with the evidence from
human genome-wide association studies suggested that altered
levels of IGF2 in -cells could confer susceptibility to diabetes.
Here, we studied the mechanisms by which IGF2 exerted its
action on -cells of Tg-IGF2 to help unravel the role that this
growth factor plays in the development of overt diabetes in
humans. To this end, we studied in detail the phenotype of
transgenic -cells at the initial stages of the diabetic process.
Local IGF2 overexpression led to -cell dysfunction as well as
down-regulation of typical markers of -cell differentiation.
Up-regulation of markers of ER stress and immune response-
related genes was also documented in islets of Tg-IGF2 mice,
and this agreed with the observed increased susceptibility to
-cell death and diabetes development. Thus, in this study we
provide evidence that local pancreatic overexpression of IGF2,
besides causing islet hyperplasia and hyperinsulinemia (27),
directly affects -cells leading to cell dysfunction and suscepti-
bility to damage and as a consequence predisposes to the onset
of diabetes.
Experimental Procedures
Animals—Heterozygous male transgenic mice expressing
either mouse Igf2 or human IFN under the control of the rat
insulin promoter-I (RIP-I) were used (27, 28). Tg-IGF2 mice
were in C57Bl6/SJL background, andTg-IFNmice, amodel of
islet lymphocytic infiltration with increased susceptibility to
autoimmune diabetes (29), were in CD1 background, and dou-
bleTg-IFN/IGF2micewere obtained by crossing the two lines
(C57Bl6/SJLCD1). Diabetes was induced as described previ-
ously (29). All mice were fed ad libitum with a standard chow
diet (2018S Teklad Global, Harlan) and maintained under con-
ditions of controlled temperature and light (12 h light/dark
cycles). When stated, mice were fasted for 16 h. Animal care
and experimental procedures were approved by the Ethics
Committee inAnimal andHuman Experimentation of theUni-
versitat Autònoma de Barcelona.
Immunohistochemistry and Histopathology—For immuno-
histochemical detection of INS, GLUT2, PDX1, MAFa, and
p62, pancreata were fixed for 12–24 h in formalin, embedded in
paraffin, and sectioned. Sectionswere then incubated overnight
at 4 °C with the following antibodies: guinea pig anti-porcine
insulin (Sigma); rabbit anti-human glucagon (Signet Labs, Ded-
ham, MA); rabbit polyclonal anti-GLUT2 (AB1342, Chemicon
International Inc., EEUU); rabbit anti-human IGF2 ((PAC1)
GroPep Ltd., Adelaide, Australia); rabbit polyclonal anti-MAFa
(Santa Cruz Biotechnology, sc-66958); rabbit polyclonal anti-
PDX1 (Millipore, AB3243); rat anti-mouse MAC-2 (Cedarlane
CL8942AP); and mouse anti-human p62 (BD Biosciences
610833) as a autophagy marker. As secondary antibodies,
peroxidase-conjugated rabbit anti-guinea pig IgG (Dako, Den-
mark), biotinylated goat anti-rabbit (Pierce), TRITC-conju-
gated goat anti-guinea pig (Molecular Probes Leiden, The
Netherlands), biotinylated goat anti-rabbit (Molecular Probes),
biotinylated rabbit anti-rat (Dako, Glostrup, Denmark), and
biotinylated horse anti-mouse (Vector Laboratories, Burlin-
game, CA) antibodies were used. Streptavidin-conjugated
Alexa 488 (Molecular Probes) or streptavidin-conjugatedAlexa
568 (Molecular Probes) were used as fluorochromes. Images
were obtained with a Nikon Eclipse E800 microscope (Nikon,
Tokyo, Japan). For laser-scanning confocal analysis, a TCS SP2
microscope (Leica Microsystems, Heidelberg, Germany) was
used.
Morphometric Analysis—-Cell mass determination was
performed as described previously (29). Macrophage infiltra-
tion was measured as the percentage of MAC-2-positive area
IGF2 Overexpression in-Cells
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per islet area in islets from three different sections per mouse,
with four animals per group.
Islets Isolation and Culture—Pancreatic islets were isolated
as described previously (29) and then cultured in RPMI 1640
medium (11 mM glucose), supplemented with 1% BSA, 2 mM
glutamine, penicillin/streptomycin at 37 °C in an atmosphere of
95% humidified air, 5% CO2. To study the effects of recombi-
nant IGF2 on -cells, after overnight culture, pools of islets
were treated with 13.5 nM recombinant IGF2 (792-MG, R&D
Systems) and then cultured for 48 h. To express Igf2 in islets,
after isolation and overnight culture, pools of islets were
infected with Igf2-expressing adenoviruses (Ad5/CMV-IGF2)
or with noncoding adenoviruses as control (Ad5/CMV-Null)
and incubated for 48 h. After treatments islets were hand-
picked and processed. For qPCR analysis, islets were cultured
overnight to recuperate from isolation stress and then hand-
picked and processed to obtain RNA.
Cell Culture—INS-1 cells were cultured in RPMI 1640
medium (11mM glucose), 2 mM glutamine, 10mMHepes, 1 mM
sodium pyruvate, 50 M 2-mercaptoethanol, and 10% FBS at
37 °C in an atmosphere of 95% humidified air, 5% CO2. For cell
culture studies, medium was modified, and 10% FBS was sub-
stituted for 1% BSA, and cells were treated with 200 nM wort-
mannin (W1628, Sigma) followed an hour later by 100 ng/ml
recombinant IGF2, or with either alone, and then cultured for
48 h.
Gene ExpressionAnalysis—For qPCR analysis, total RNAwas
extracted from isolated islets using Tripure Isolation Reagent
(Roche Applied Science) and RNeasy mini kit (Qiagen, Hilden,
Germany). Total RNA (1 g) was retrotranscribed using the
Transcriptor First Strand cDNA synthesis kit (Roche Applied
Science). RT-PCR was performed using LightCycler 480 SYBR
Green IMasterMix (Roche Applied Science). The primers used
for murine islets and INS-1 cells (rat) are listed in the Table 1.
Results were analyzed using the mathematical model of Pfaffl
(30). All sampleswere processed in triplicate, and ameanCtwas
calculated. The Ct for each transcript of interest was normal-
ized by theCt obtained for the reference gene RplpO. Then, the
relative expression of each gene in each sample was calculated
by dividing the value obtained for each sample by the mean of
wild-type/control values.
Hormone and Metabolite Assays—Blood glucose levels and
serum insulin concentrations were measured as described pre-
viously (29). The concentration of serum glucagon was deter-
mined by radioimmunoassay with the Millipore glucagon
radioimmunoassay kit (EMD Millipore Corp., Billerica,
MA). Glucose tolerance was evaluated as described previ-
ously (29). For insulin release determination, glucose (3 g/kg
body weight) was injected intraperitoneally, and venous
blood was collected from tail vein at 0, 2, 5, 15, and 30 min in
pre-chilled tubes (Microvette CB 300, SARSTEDT) and
immediately centrifuged to separate plasma, which was
stored at 20 °C. Insulin levels were measured by ELISA
(Crystal Chemical, Chicago).
MicroarrayAnalysis—RNA samples were obtained following
Affymetrix recommendations (Expression Analysis Technical
Manual).Microarray analysis was performed by Progenika (Bil-
bao, Spain). The final gene list contained only those probe sets
with ap 0.05. For the interpretation, cross-checking and visu-
alization of the data, FatiGO term enrichment (release date
11/20/2010), Database for Annotation, Visualization and Inte-
gratedDiscovery (DAVID; david.abcc.ncifcrf.gov), Kyoto Ency-
clopedia of Genes and Genomes, and GeneCodis were used.
Array data have been submitted to MIAMExpress (E-MEXP-
3786).
Statistical Analysis—All values are expressed as the mean
S.E. Differences between groups were compared by Student’s t
TABLE 1
Primers used for murine islets and INS-1 cells (rat)
Gene Forward primer (5 to 3) Reverse primer (5 to 3)
Mouse
Foxa2 5GAG-CAG-CAA-CAT-CAC-CAC-G3 5CGT-AGG-CCT-TGA-GGT-CCA-T3
Pdx1 5GAA-ATC-CAC-CAA-AGC-TAC-G3 5CGG-GTT-CCG-CTG-TGT-AAG3
RplpO 5TCC-CAC-CTT-GTC-TCC-AGT-CT3 5ACT-GGT-CTA-GGA-CCC-GAG-AAG3
Ins 5GCG-ATT-GTG-GAT-CAG-TGC-T3 5AGG-TGG-GCC-TTA-GTT-GCA-C3
Gck 5ATG-ACA-GAG-CCA-GGA-TGG-AG 5CGG-CTC-ATC-ACC-TTC-TTC-AG3
Glut2 5CTG-GAG-CCC-TCT-TGA-CGG-GA3 5CCA-GTC-CTG-AAA-TTA-GCC-CAC-A3
Serca2 5GTC-CTA-ACT-GTG-GTG-TTT-TCC-TC3 5GTT-TAG-GAA-GCC-GTT-ACT-CCA-G3
Chop 5GCG-ACA-GAG-CCA-GAA-TAA-CA3 5GAT-GCA-CTT-CCT-TCT-GGA-ACA3
B2-microglobulin 5ACT-CCA-AGA-CCC-AGA-AAC-TGT-C3 5ACT-GGT-AGG-AGT-AGG-GAT-GCA-C3
H2-Aa 5CTC-TGA-TTC-TGG-GGG-TCC-T 3 5ACC-ATA-GGT-GCC-TAC-GTG-GT3
2/NeuroD1 5CTC-TGA-TTC-TGG-GGG-TCC-T3 5ACC-ATA-GGT-GCC-TAC-GTG-GT3
Hnf4a 5TGC-CAA-CCT-CAA-TTC-ATC-CA3 5GCT-CGA-GGC-TCC-GTA-GTG-TT3
Mafa 5AGG-AGG-AGG-TCA-TCC-GAC-TG3 5CTT-CTC-GCT-CTC-CAG-AAT-GTG3
Xbp1s 5GCT-GAG-TCC-GCA-GCA-GGT3 5ACA-GGG-TCC-AAC-TTG-TCC-AG3
XBPt 5TCA-GTT-TCC-TCC-GCA-GCG-CTT-T3 5GCT-GCC-GCT-CAT-GGT-ACC-CG3
Igf2r 5TCT-GTG-TTG-GCT-CGT-CAC-TC3 5CCG-GTG-ACA-GAC-GTT-GAT-GA3
Insr-B 5GCC-AGT-GAG-TGC-TGC-TCA-T3 5TAC-TGT-CCT-CGG-CAC-CAT-T3
Insr-A 5CCC-ACC-CTT-TGA-GTC-TGA-TG3 5GCT-TTC-GGG-ATG-GCC-T3
Gcg 5GGC-ACA-TTC-ACC-AGC-GAC-TA3 5GTC-CCT-TCA-GCA-TGC-CTC-TC3
Rat
Foxa2 5CCA-GAC-AAC-GCG-AGT-CCT3 5ACG-GCT-CCC-AGC-ATA-CTT-T3
Pdx1 5CTG-TCG-TGC-CAT-GTG-AAC-C3 5TTC-TCT-AAA-TTG-GTC-CCA-GGA-A3
RplpO 5GAT-GCC-CAG-GGA-AGA-CAG3 5CAC-AAT-GAA-GCA-TTT-TGG-GTA-G3
INS 5 GCT-CTG-TAC-CTG-GTG-TGT-GG 3 5 CCA-AGG-TCT-GAA-GAT-CCC-CG 3
Gck 5GCC-CAG-TTG-TTG-ACT-CTG-GT 5CAT-CAC-CTT-CTT-CAG-GTC-TTC 3
GLUT2 5TGA-AGG-ATC-TGC-TCA-CAT-AGT-CA 3 5CCA-ACA-TGG-CTT-TGA-TCC-TT 3
Serca 5TGT-TAA-TCA-AGA-CAA-AAA-GAA-CAT-GC3 5GGA-TCT-TGC-CGA-TCT-CAG-TAT-T3
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test. A p value less than 0.05 was considered statistically
significant.
Results
Local IGF2 Overexpression Impairs Islet Function—Trans-
genic mice overexpressing IGF2 specifically in -cells (Tg-
IGF2) have disrupted islet structure and islet hyperplasia and
develop a pre-diabetic state (27). To study the role of IGF2 in
-cell function at the initial stages of the diabetic process, we
performed a glucose tolerance test and in vivo insulin release
(IR) test on 4-month-old mice. Tg-IGF2 mice showed glucose
intolerance (Fig. 1A) (27) and were accompanied by reduced
insulin release (Fig. 1B). In particular, the first phase of insulin
secretion in response to glucosewas greatly diminished in these
mice (Fig. 1B), suggesting an impaired secretory response by
-cells. Tg-IGF2 mice were, however, hyperinsulinemic (WT,
1.2  0.16 ng/ml; Tg-IGF2, 2.2  0.19 ng/ml, p  0.05 (27)),
which reflected the fact that these animals have a -cell mass
3-fold higher than WT littermates (27). In contrast, Tg-IGF2
mice presented a normal -cell mass (27), and no differences
were observed in the levels of islet glucagon mRNA (1  0.35
versus 0.81  0.19 relative units for wild type and Tg-IGF2,
respectively, p  0.31) or serum glucagon (WT  100.9  8.2
versus Tg-IGF2 131.2 26.5 pg/ml, p 0.21). In agreement
with the abnormal insulin release shown by Tg-IGF2 upon glu-
FIGURE 1. Local overexpression of IGF2 alters islet functionality. A, Tg-IGF2mice showed altered glucose tolerance test at 4 months of age. Three-month-
old WT (white circle) and Tg-IGF2 (black circle) mice were given an intraperitoneal injection of 2 mg of glucose/g bw, and blood glucose was measured at the
indicated times as described under “Experimental Procedures.” Results are expressed as mean S.E. of 10 animals/group. *, p 0.05. B, in vivo insulin release
test after intraperitoneal glucose injection (3g/kgbw) to4-month-oldWTmice (white circles) andTg-IGF2mice (black circles),n10animals/group (*,p0.05).
C, analysis of the expression of -cell glucose sensor genes,Gck and Slc2a2/Glut2, by qPCR onWT (white bars) and Tg-IGF2 (black bars) islets from 4-month-old
mice. Data are mean S.E. of at least three pools of islets from eight animals/group. **, p 0.01. D, immunohistochemical detection of INS (red) and GLUT2
(green) in pancreatic sections of 3-month-old WT and Tg-IGF2 mice. Original magnification 400 (scale bar, 50 m). E, electron microscopy of -cells in
pancreatic islets isolated from 4-month-old WT and Tg-IGF2 mice. Tg-IGF2 -cells presented altered ultrastructure (10,000) (scale bar, 2 m). Inset images
show secretory granules in more detail (80,000) (scale bar, 0.2 m).
IGF2 Overexpression in-Cells
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cose stimulation, the -cell glucose sensors, solute carrier fam-
ily member 2 (Slc2a2 or Glut2) and glucokinase (Gck), were
down-regulated in transgenic islets (Fig. 1C). Immunohisto-
chemical analysis further confirmed the dramatic reduction in
SLC2A2 protein in insulin-positive cells in these animals (Fig.
1D). Moreover, the ultrastructural analysis of -cells by elec-
tron microscopy revealed an increased number of immature
insulin secretory granules with low or intermediate electron
density occupying most of the cytoplasm of Tg-IGF2 -cells
(Fig. 1E). Altogether, these results provide evidence of -cell
dysfunction and inadequate secretory response in Tg-IGF2
mice.
To gain insight into the IGF2-mediated molecular mecha-
nisms that could account for-cell dysfunction, we determined
the expression of key genes involved in -cell functionality. By
qPCR, we observed that Insulin I mRNA levels were decreased
in Tg-IGF2 compared withWT islets (Fig. 2A), and this agreed
with the loss of the secondphase of insulin release (Fig. 1A). The
expression of critical transcription factors for insulin produc-
tion such as forehead box A2 (Foxa2), neurogenic differentia-
tion 1 (Neurod1), hepatic nuclear factor 4 (Hnf4), v-maf
musculoaponeurotic fibrosarcoma oncogene family (Mafa),
and pancreatic and duodenal homeobox 1 (Pdx1) was also
down-regulated (Fig. 2, B–F). Decreased production of MAFa
and PDX1 was further confirmed by immunohistochemical
analysis (Fig. 2,G andH). In addition, we performedmicroarray
analysis on islets isolated from Tg-IGF2 and WT mice. After
normalization and statistical filtering of the data,more than 300
genes with a 2-fold up- or down-regulation were identified,
with the majority of them down-regulated and involved,
according to gene ontology classification, in insulin secretion,
development, cellular stress, immunity, transport, electron
transport chain, and replication (Table 2). Noticeably, there
was down-regulation of several genes characteristic of fully dif-
ferentiated and functional -cells, such as proprotein conver-
tase subtilisin/kexin type 1 (Pcsk1/PC1/3), forkhead box A2
FIGURE 2. IGF2 overexpression leads to changes in -cell phenotype. A–F, confirmation of the differential gene expression of -cell markers in WT (white
bars) andTg-IGF2 (blackbars) islets from4-month-oldmicebyqPCR.Data are expressedasmeanS.E. of at least threepools of islets fromeight animals/group.
*, p 0.05.G, immunohistochemical detection of INS (red) andMAFa (green) in pancreatic sections from3-month-oldmice. Originalmagnification400 (scale
bar,50m).H, immunohistochemical detectionof INS (red) andPDX1 (green) in pancreatic sections from3-month-oldmice.Originalmagnification400 (scale
bar, 50 m).
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(Foxa2), and lipin 1 (lpin1) involved in insulin secretion, insulin
promoter factor 1, homeodomain transcription factor (Ipf1/
Pdx1), and solute carrier family 2, member 2 (Slc2a2). Alto-
gether, these results support the notion that -cells undergo a
process of dedifferentiation resulting in functional alterations
due to the overexpression of IGF2.
IGF2 Overexpression Induces ER Stress in -Cells—It has been
reported that endoplasmic reticulum (ER) stress is involved in
TABLE 2
Differentially expressed genes
Microarray expression analysis in islets from WT and Tg-IGF2 2-month-old mice. Classification of up- and down-regulated genes according to their biological function
reported in the literature. RNA was isolated from three pools of islets from nine animals per group.
Gene description Gene symbol
Fold
change
p
value RefSeq
Development
Myeloid ecotropic viral integration site-related gene 1 Meis2 0.67 0.03160 NM 010825
ISL1 transcription factor, LIM/homeodomain (islet 1) Isl1 0.42 0.04980 NM_021459
Insulin promoter factor 1, homeodomain transcription factor Pdx1 0.58 0.03740 NM_ 008814
Notch gene homolog 3 (Drosophila) Nocth3 2.11 0.00484 NM 00876.2
Insulin secretion
Activating transcription factor 2 Atf2 0.45 0.02090 NM_009715
Calcyphosphine 2 Caps2 0.35 0.03340 NM_178278
Dipeptidylpeptidase 4 Dpp4 0.60 0.01890 NM 010074
ERO1-like (Saccharomyces cerevisiae) /// hypothetical gene supported by AK009667;
NM_01577
Ero1l /// LOC434 0.44 0.00139 NM_015774
Forkhead box A2 Foxa 2 0.58 0.04580 NM_010446
Gap junction membrane channel protein 9 Gja9/Cx36 0.38 0.03470 NM 010290
Potassium channel, subfamily K, member 16 Kcnk16 0.52 0.00696 NM_029006
Lipin 1 Lpin1 0.59 0.03970 NM 172950
Proprotein convertase subtilisin/kexin type 1 Pcsk1/PC1/3 0.46 0.01790 NM 13628
N-Ethylmaleimide-sensitive fusion protein Nsf 0.70 0.03610 NM_008740
Rap guanine nucleotide exchange factor (GEF) 3 Rapgef3 2.15 0.02210 NM_144850
Synaptotagmin-like 4 Sytl4 0.33 0.04260 NM_013757
Transthyretin Ttr 0.40 0.02690 NM_013697
Urocortin 3 Ucn3 0.23 0.00894 NM_031250
Metal-response element-binding transcription factor 1 Mtf1 0.52 0.03510 NM_008636
Stress
Autocrine motility factor receptor Amfr 0.62 0.02980 NM_011787
Activating transcription factor 2 Atf2 0.45 0.02090 NM_009715
ATPase, Cu2 transporting, -polypeptide Atp7a 0.73 0.03470 NM_009726
Der1-like domain family, member 2 Derl2 0.53 0.01260 NM_033562
ERO1-like (S. cerevisiae) /// hypothetical gene supported by AK009667; NM_01577 Ero1l 0.44 0.00139 NM_015774
F-box and leucine-rich repeat protein 5 Fbxl5 0.65 0.03600 NM_178729
Forkhead box M1 Foxm1 1.33 0.03840 NM_027697
Heat shock protein 1 Hspb1 1.91 0.02100 NM_013560
Methyl CpG-binding protein 2 Mecp2 0.63 0.02480 NM_010788
Metal-response element-binding transcription factor 1 Mtf1 0.52 0.03510 NM_008636
Polo-like kinase 3 (Drosophila) Plk3 0.42 0.00505 NM_013807
Autophagy 10-like (S. cerevisiae) Atg10 0.64 0.04880 NM_025770
Immune response
Alanyl-tRNA synthetase Aars 0.68 0.04430 NM 146217
Glutamic acid decarboxylase 1 Gad1 0.21 0.01030 NM 008077
Cathepsin H Ctsh 2.42 0.02940 NM_007801
Immunoglobulin heavy chain (J558 family) Igh-VJ558 8.33 0.00888 NM_134051
Endothelial differentiation, sphingolipid G-protein-coupled receptor, 3 Edg3 2.96 0.03100 NM_010101
Histocompatibility 2, class II antigen A,  H2-Aa 2.70 0.01940 NM_010378
Transport
Solute carrier family 9 (sodium/hydrogen exchanger), isoform 3 regulator 2 Slc9a3r2 1.50 0.03590 NM_023055
Solute carrier family 35, member 3 Slc35a3 0.66 0.04800 NM_144902
Solute carrier family 2 (facilitated glucose transporter), member 2 Slc2a2 0.24 0.04170 NM_031197
solute carrier family 20, member 2 Slc20a2 0.60 0.04070 NM_011394
Solute carrier family 12, member 7 Scl12a7 0.57 0.03840 NM_011390
Solute carrier family 4, sodium bicarbonate cotransporter, member 7 Slc4a7 0.47 0.01890 NM_001033270
Solute carrier family 2 (facilitated glucose transporter), member 5 Slc2a5 0.61 0.04950 NM_019741
Potassium large conductance calcium-activated channel, member 2 Kcnmb2 0.50 0.00456 NM_028231
Activating transcription factor 2 Atf2 0.45 0.02090 NM_009715
Calcium channel, voltage-dependent, 2 subunit Cacnb2 0.68 0.02080 NM_023116
Transport chain
ATPase, H-transporting, V1 subunit B, isoform 2 Atp6v1b2 0.77 0.04870 NM_007509
ATPase, H-transporting, V0 subunit C Atp6v0c 0.61 0.04770 NM_009729
ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 Atp8a1 0.62 0.04630 NM_009727
ATPase, Cu2-transporting, -polypeptide Atp7a 0.64 0.04200 NM_009726
ATPase, Ca2-sequestering Atp2c1 0.55 0.03890 NM_175025
ATPase, Ca2-transporting, cardiac muscle, slow twitch 2 Atp2a2 0.49 0.03040 NM_009722
Cytochrome P450, family 4, subfamily v, polypeptide 3 Cyp4v3 0.53 0.03790 NM_133969
NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2 Ndufc2 0.60 0.03220 NM_024220
Replication
Cyclin D2 Ccnd2 0.49 0.04340 NM_009829
Prolactin receptor Prlr 0.45 0.02650 NM_011169
B-cell translocation gene 1, anti-proliferative Btg1 0.68 0.03340 NM_007569
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-cell failure (31). Electron microscopy observation of Tg-IGF2
-cells showedanexpandedERnetwork (Fig. 3A,arrows),which is
indicative of ER stress induced by the unfolded protein response
(32). Accordingly, microarray analysis (Table 2) and qPCR (Fig.
3B) revealed down-regulation of the ATPase, Ca2-transporting
cardiac muscle, slow twitch 2 (Atp2a2/Serca2) gene in Tg-IGF2
islets. The SERCAprotein regulatesCa2 flux in andout of the ER
and, as a consequence, controls proper protein folding (33).More-
over,markers of ER stress such as spliced x-box-binding protein 1
(Xbp1s) and DNA damage-inducible transcript 3 (Ddit3/Chop)
were also up-regulated in Tg-IGF2 (Fig. 3B).
Autophagy has also been associated with ER stress and plays
an important role in diabetes pathogenesis (34). Electron
microscopy analysis revealed the presence in Tg-IGF2 -cells
of autophagic bodies or autophagosomes, identified as portions
of the cytoplasm surrounded by a double membrane (Fig. 3C).
An increase in the immunohistochemistry signal intensity of
SQSTM1 (p62), a ubiquitin-binding protein also known as
sequestosome 1 that co-localizes to autophagic bodies (35), was
detected in most of the unstructured islets of Tg-IGF2 mice
(Fig. 3D), confirming an increase in autophagy in Tg-IGF2
islets.
IGF2 Is Sufficient to Trigger -Cell Dysfunction—To discard
the possibility that the -cell dysfunction observed in Tg-IGF2
mice was due to IGF2 overexpression from early embryonic
development, islets isolated fromadultWTanimalswere trans-
FIGURE 3. ER stress and autophagy in Tg-IGF2 islets. A, electron microscopy of -cells in islets of 4-month-old WT and Tg-IGF2 mice. Rough endoplasmic
reticulum showing a normal lamellar arrangement is observed inWT,whereas Tg-IGF2 presented altered ER lamellar arrangement and dilatations as indicated
by red arrows (composite image). Original magnification 100,000. B, validation of differential gene expression of ER stress markers in WT (white bars) and
Tg-IGF2 (black bars) islets from 4-month-old mice by qPCR. Data are expressed as mean S.E. of at least three pools of islets from eight animals/group. *, p
0.05; **, p 0.01. C, electronmicroscopy of-cells in islets of 4-month-old Tg-IGF2mice. An autophagic body, a cytoplasmic inclusion surrounded by a double
membrane containing part of the cytoplasm, is indicated by red arrows in an image corresponding to Tg-IGF2 -cells (80,000). D, immunohistochemical
detection of insulin (red) and LGAL3/p62 (green) in pancreatic sections from 3-month-oldmice. Inset images show in detail the positive p62 signal observed in
-cells of Tg-IGF2 islets. Scale bar, 8 m.
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duced in vitro with adenoviral vectors encoding murine Igf2
(Ad/IGF2) or with null vectors (Ad/Null) that served as con-
trols. Islets transduced with Ad/IGF2 vectors presented a sim-
ilar phenotype to that observed in Tg-IGF2 islets, e.g. decreased
Slc2a2, Pdx1, insulin I, and Atpa2/Serca2 expression and
increased levels of Ddit3/Chop, although changes in Serca2
and Ddit3/Chop did not reach statistical significance (Fig. 4, A
and B). Thus, IGF2 overexpression in adult islets is sufficient to
alter-cell functionality by diminishing insulin production and
inducing ER stress.
To study whether the phenotype of Tg-IGF2- and Ad/IGF2-
transduced islets was due to the forced overexpression of IGF2
rather than a direct effect of IGF2 on-cells, islets isolated from
adult WT mice were also incubated for 48 h with recombinant
IGF2 protein (rIGF2) tomimic the chronic exposure to IGF2 of
Tg-IGF2 islets. Similarly to Tg-IGF2 and Ad/IGF2-transduced
islets, rIGF2-treated islets presented a significant decrease in
Slc2a2 and insulin I expression and a nonstatistically significant
down-regulation of Gck, Pdx1, and Atp2a2/Serca2 (Fig. 4C).
Similar results were obtained in rIGF2-treated INS-1 cells (data
not shown).
Given that IGF2 binds with high affinity to the insulin
(INSR), insulin-like growth factor 1 (IGF1R), and IGF2 recep-
tors, we quantified the expression of these receptors inTg-IGF2
islets. No differences were observed in the expression of IGF2R,
IGF1R, or INSR-B (data not shown). However, a moderate
(about 40%) statistically significant decrease in INSR-A expres-
sion was documented in Tg-IGF2 islets (WT 1.03 0.11 versus
Tg-IGF2 0.67 0.05, p 0.03). Next, we analyzed the effects of
IGF2 on gene expression by inhibiting both INSR and IGF1R
downstream signaling pathways using wortmannin, a PI3K
inhibitor (36). INS-1 cells cultured in the presence of rIGF2
showed decreased expression of markers of -cell identity (Fig.
4D), which recapitulated the observations made in Tg-IGF2
FIGURE 4. IGF2 effects on adultWT islets.A, expression of-cellmarkers by qPCR analysis inWT islets transducedwith null control vector (Ad/Null,white bars)
or adenovirus expressing IGF2 (Ad/IGF2,blackbars).B,expressionof ER stressgenesbyqPCR in the sameadenovirus-transduced islets. Threepools of islets from
eight animals/group were used. C, gene expression analysis of -cell markers by qPCR in WT islets incubated for 48 h with either vehicle (white bars) or 100
ng/ml recombinant IGF2 protein (black bars). Three pools of islets from eight animals/group were used. D, analysis by qPCR of Foxa2, Slc2a2/Glut2, and Gck
genes in INS-1 cells treated for 48 h with vehicle (white bars), 100 ng/ml recombinant IGF2 protein (black bars), 200 nM of the PI3K inhibitor wortmannin (light
gray bars), or both (dark gray bars). Results shown represent the data obtained for at least six wells/condition and from three independent experiments. Data
are expressed as mean S.E. *, p 0.05; **, p 0.01 versus vehicle-treated cells. #, p 0.05, and ##, p0.01 versus recombinant IGF2-treated cells.
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islets (Figs. 1B and 2). The addition of wortmannin per se
altered the expression of Foxa2, Slc2a2, and Gck (Fig. 4D).
Despite this unexplained observation, we did document a sig-
nificant inhibition of the effects of rIGF2 by wortmannin treat-
ment (Fig. 4D), indicating that at least partially the IGF2 effects
on -cell expression were mediated by PI3K activation.
IGF2 Transgenic Islets Are More Susceptible to -Cell
Damage—Microarray analysis of Tg-IGF2 islets showed altered
expression of several genes involved in the immune response,
such as cathepsin H (Ctsh), immunoglobulin heavy chain (J558
family, Igh-VJ558), endothelial differentiation, sphingosine 1-
phosphate receptor 3 (Edg3), and histocompatibility 2, class II
antigen A,  (H2-Aa) (data not shown). Although CD4- and
CD8- positive lymphocytes could not be detected in pancreata
fromTg-IGF2mice (Table 2), immunostaining against LGAL3/
MAC-2 revealed the presence of macrophages infiltrating Tg-
IGF2 islets (Fig. 5, A and B). qPCR analysis confirmed the
increased expression of H2-Aa and 2-microglobulin (B2m)
(Fig. 5C), indicating an up-regulation ofmajor histocompatibil-
ity complex (MHC) class I and II antigens in Tg-IGF2 islets,
likely due, at least in part, to macrophage infiltration. These
results suggested that Tg-IGF2 -cells could be more suscepti-
ble to immune cell-mediated damage.
To verify this hypothesis and to determine the degree of sen-
sitivity to damage of their -cells, Tg-IGF2 mice received five
daily consecutive injections of very low doses of streptozo-
tocin (STZ), 20 mg/kg bw, a dose too low to affect WT mice
(29). In contrast to WT mice, which remained normoglyce-
mic, Tg-IGF2 mice showed a progressive increase in blood
glucose levels (Fig. 6A) with 	45% of transgenics becoming
diabetic 6 months post-STZ administration (Fig. 6B). This
increased incidence of diabetes was due to a drastic reduc-
tion in -cell mass in STZ-treated Tg-IGF2 mice (Fig. 6, C
and D) even though these mice have a pre-STZ -cell mass
3-fold higher than that of WT mice (27). Thus, these results
confirmed that local overexpression of IGF2 in -cells in-
creased susceptibility to injury caused by an external toxin,
such as STZ.
FIGURE 5. IGF2 overexpression leads to islet macrophage infiltration. A, macrophage infiltration was determined by LGAL3/MAC-2 immunostaining on
islet sections from 3-month-old mice. Original magnification 10 (scale bar, 100 m) and insets 40 (scale bar, 50 m). B, quantification of LGAL3/MAC-2-
positive area. Data are expressed asmean S.E. of percentage of LGAL3/MAC-2-positive islet areas/total islet areas. n 5 animals/group. WT (white bars) and
Tg-IGF2 (black bars). C, analysis of gene expression by qPCR of histocompatibility 2, class II antigen A (H2-Aa), -2 microglobulin (B2-m) genes in WT (white
bars), and Tg-IGF2 (black bars) islets from 4-month-old mice. Results are expressed as mean S.E. of at least three pools of islets from eight animals/group. *,
p 0.05; **, p 0.01.
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To further study the increased susceptibility of Tg-IGF2
-cells to damage, Tg-IGF2 mice (C57Bl6/SJL background)
were crossed with transgenic mice expressing human inter-
feron  specifically in -cells (Tg-IFN, CD1 background).
Tg-IFNmice have islet lymphocytic infiltration and increased
susceptibility to develop autoimmune diabetes with similar
characteristics to humans type 1 diabetes (29). Although WT,
Tg-IGF2, and Tg-IFN mice (all in 50% C57Bl6/SJL-50% CD1
background) remained normoglycemic during the 12-month
follow-up, double transgenic mice Tg-IFN/IGF2 (50%
C57Bl6/SJL-50% CD1 background) were highly hyperglycemic
as early as 1 month of age (Fig. 7A), with 75% of them develop-
ing spontaneous diabetes during the first 2 months of life (Fig.
7B). At 3 month of age, WT and Tg-IFNmice were normoin-
sulinemic and had normal -cell mass, whereas Tg-IGF2 mice
showed hyperinsulinemia and -cell hyperplasia (Fig. 7, C and
D). -Cell hyperplasia in Tg-IGF2mice was lower that what we
previously described (Fig. 6D) (27). This was likely due to a
variation in the genetic background from 100% C57Bl6/SJL in
the original study, a backgroundmore prone to islet hyperplasia
(37, 38), to 50% C57Bl6/SJL-50%CD1 in the Tg-IGF2 that were
littermates of Tg-IFN/IGF2. In agreement with the high inci-
dence of spontaneous diabetes, double Tg-IFN/IGF2 mice
had lower circulating levels of insulin anddecreased-cellmass
(Fig. 7, C and D).
Discussion
Our group previously reported that local overexpression of
IGF2 in -cells predisposes to the development of T2D (27).
Mice overexpressing IGF2 are mildly hyperglycemic, hyperin-
sulinemic, and insulin-resistant, and when subjected to a high-
fat diet they develop overt diabetes (27). The increased -cell
mass and the high degree of islet disorganization present in
Tg-IGF2mice could account for the islet functional failure that
characterizes these animals. The molecular bases underlying
the observed phenotype, however, were not fully understood
nor to what extent the overexpression of IGF2 during embry-
onic development contributed to the process. In this study, we
demonstrate that -cell-restricted IGF2 overexpression trig-
gers -cell dedifferentiation and dysfunction and increases
their susceptibility to damage, highlighting the important role
that this growth factor may have in the progression of T2D.
In our previous work, we reported that insulin expression in
total pancreata and in vitro glucose-stimulated insulin secre-
FIGURE6.Transgenic IGF2micearemore sensitive to streptozotocin treatment.A,bloodglucose levelsweremonitored in fedmice for 6months following
treatment with very low doses of STZ for 5 consecutive days (20 mg/kg bw). WT mice (white squares) and transgenic IGF2 mice (blue circles) (n 15 animals/
group).B, cumulative incidenceof diabetesbefore andafter STZ treatment.Micewere considereddiabeticwhen twoconsecutiveglucosemeasurementswere

250 mg/dl. WT mice (white squares) and transgenic IGF2 mice (black squares) (n  15 animals/group). C, insulin immunostaining of pancreatic sections 6
months after STZ treatment. Transgenic IGF2mice clearly presented fewer insulin-positive cells. Representative images, original magnification10 (scale bar,
100 m). D, -cell mass was measured 6 months after STZ treatment in WT (white bars) and Tg-IGF2 (black bars) mice. Nine pancreatic sections from each
individual mouse (fourmice/group) were analyzed as described under “Experimental Procedures.” Results are expressed asmean S.E. #, p 0.05 versusWT;
**, p 0.01 versus Tg-IGF2-STZ.
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tion by isolated islets were greater inTg-IGF2 than inWTmice,
which agreed with the hyperinsulinemia described in trans-
genic animals (27). For the in vitro experiments, an equal num-
ber ofWTandTg-IGF2 isletswere used, but because transgenic
islets are considerably larger, this study was not illustrative of
the amount of insulin produced by each -cell. In this work, we
observed that Tg-IGF2mice secreted less insulin in response to
a glucose overload than WT mice. Other animal models with
islet hyperplasia also display impaired insulin secretion, such as
the IR/IRS-1/ and IRS1/ knock-outmice (39, 40), and this
has been attributed to altered -cell functionality. Noticeably,
-cell dysfunction and alterations in insulin secretion have
been described to precede insulin resistance in human patients
at risk of developing T2D (41, 42). Similarly, Tg-IGF2 mice
show glucose intolerance from an early age (2 months) and
develop insulin resistance when they are older than 4 months
(27). Thus, -cell failure would be a primary defect and not just
a simple consequence of diabetes progression in this model. A
clear reduction in the expression of themain glucose sensors of
the-cell, theglucosetransporterGLUT2andtheglucose-phos-
phorylating enzyme glucokinase, was documented in islets
from Tg-IGF2mice or in wild-type islets treated with recombi-
nant IGF2 or with adenoviral vectors that mediate overexpres-
sion of IGF2 in -cells. In addition, microarray profiling analy-
sis of Tg-IGF2 islets revealed alterations in the expression of
several genes involved in insulin secretion and cell transport, as
well as of several transcription factors important for -cell dif-
ferentiation and functionality, such as Pdx1, Isl1, MafA, and
Beta2/Neurod1. These changes could partially explain the clear
-cell dysfunction observed in our transgenic mice, mainly the
reduced insulin synthesis and secretion, and the dedifferenti-
ated phenotype of Tg-IGF2 -cells. Other type 2 diabetic ani-
malmodels, such as db/dbmice and Zucker andGoto-Kakizaki
rats, which have similar characteristics to Tg-IGF2 mice, i.e.
islet hyperplasia, hyperinsulinemia, insulin resistance, and
altered insulin secretion and response to glucose, also show a
partial loss of-cell phenotype (12, 43).Moreover,mice lacking
FoxO1 specifically in -cells have high blood glucose concen-
tration associated with reduced -cell mass that was attributed
to -cell dedifferentiation rather than to -cell death (6). A
recent study proposes that -cell dedifferentiation, rather than
apoptosis, is the main mechanism of loss of insulin-positive
FIGURE 7. Double IFN/IGF2 transgenic mice develop diabetes spontaneously. A, blood glucose levels were monitored in fed WT (white squares), trans-
genic IFN (gray circles), transgenic IGF2 (black circles), and double transgenic IFN/IGF2mice (blue-white rhombus) mice from 0.5 to 12months of age, n 40
animals/group. B, cumulative incidence of diabetes in WT (white squares), transgenic IFN (gray circles), transgenic IGF2 (black circles), and double transgenic
IFN/IGF2 (black rhombus) mice, n 40 animals/group. Mice were considered diabetic when two consecutive glucose measurements were
250 mg/dl. C,
serum insulin levels at 3months of age inWT (white bars), Tg-IFN (light gray bars), Tg-IGF2 (black bars), and double Tg-IGF2/IFN (dark gray bars) mice. Results
are expressed asmean S.E. of 15 animals/group. *, p 0.05 versusWT.D,-cell mass wasmeasured at 3months of age inWT (white bars), Tg-IFN (light gray
bars), Tg-IGF2 (black bars), and double Tg-IFN/IGF2 (dark gray bars) mice. Nine pancreatic sections from each individual mouse (four mice/group) were
analyzed as described under “Experimental Procedures.” Results are meansS.E. of six animals/group. *, p 0.05; **, p 0.01 versusWT.
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cells in a mouse model of T2D and that intensive insulin ther-
apy, through the reversal of hyperglycemia, leads to re-differ-
entiation of -cells to a mature phenotype (9). These observa-
tions suggest that -cell dedifferentiation is a common process
in T2D (6) and that at least some forms of diabetesmellitusmay
result from loss of -cell identity (7, 8). Our study supports this
notion by demonstrating that IGF2 alone is capable of inducing
changes in the-cell phenotype, increasing the susceptibility to
develop diabetes. Of note, when Tg-IGF2 mice were treated
with low nondiabetogenic STZ doses,	45% of transgenicmice
developed overt diabetes despite the fact that GLUT2, the
transporter by which STZ enters the -cell, was down-
regulated.
Tg-IGF2 cells also presented other important cellular altera-
tions. ER stress has been proposed as a mechanism to explain
-cell dysfunction and death in T2D (12, 44). Tg-IGF2 islets
showed signs of ER stress. By electronmicroscopy, we observed
the characteristic dilatations of the ER that accompany ER
stress (31). In addition, the expression of markers of ER stress
such as Xbp1s and Ddit3/Chop was increased, and the expres-
sion of Serca2, the main transporter of Ca2 to the ER (45), was
reduced. Some of these modifications in the expression of ER
stress markers were also observed in wild-type islets treated
with adenoviral vectors encoding Igf2 or in wild-type islets
treated with recombinant protein, indicating that IGF2 per se
was sufficient to induce ER stress in -cells.
On the other hand, Tg-IGF2 islets showed increased expres-
sion of genes involved in the immune response, such as MHC
class I and II, and a considerable number of macrophages infil-
trated transgenic islets. Similarly, islets from Goto-Kakizaki
rats, a model of T2D, have macrophage infiltration and an
increased number of MHC-II-positive cells (46, 47). Macro-
phage infiltration has also been observed in islets from human
T2D subjects (41). The immunological alterations observed at
the islet level could probably predispose IGF2 islets to be more
susceptible to immune cell-mediated attack and-cell damage.
Indeed, double transgenicTg-IFN/IGF2 spontaneously devel-
oped overt diabetes at a very early age, without the need for
administering STZ. These results indicate that islets overex-
pressing Igf2 have increased susceptibility to -cell death. In
addition, increased macrophage infiltration and expression of
MHC-IImolecules could contribute to the increased sensitivity
to STZ of Tg-IGF2 -cells.
The reproducibility of the observations made in Tg-IGF2
islets or in wild-type islets treated with IGF2 recombinant pro-
tein or with Igf2-encoding adenoviral vectors supports the idea
that most of the observations made were direct effects of IGF2.
Therefore, these observations were not the result of the over-
expression of the growth factor during fetal pancreatic
development.
The binding of IGF2 to IGF-II/Man-6-P receptor, its own
receptor, has no other biological function than clearing IGF2
from serum and targeting it for degradation in lysosomes (48),
thus balancing IGF2 activity by controlling the extracellular
levels of IGF2 (49). Our in vitro studies demonstrated that IGF2
effects on -cells were at least partially mediated through
IGF1R or INSR signaling, because inhibition of the common
downstream effector PI3K reversed the down-regulation of
Glut2, Foxa2, and Gck expression. IGF2 can bind to INSR. In
particular, isoform A (INSR-A) binds IGF2 with high affinity,
and its activation by IGF2 elicits a unique signaling pathway
different from that of insulin (50). Indeed, we observed a down-
regulation of the INSR-A receptor, similar to what had previ-
ously been documented after hyperstimulation with insulin in
various target tissues (51). Moreover, IGF2 can act through
IGF1R andmay even act through hybrid INSR-A/IGF1R recep-
tors (52). Although we have observed detrimental effects of
IGF2 on -cell functionality, which resulted in increased sensi-
tivity to -cell damage, others have demonstrated that the
interaction of IGF2 with the IGF1R is required for GLP-1-in-
duced protection against -cell apoptosis (53).
In summary, although there is still no direct evidence of the
increase of IGF2 in T2D in humans, this study demonstrates
that local overexpression of IGF2, specifically in -cells, causes
profound changes in -cells that lead to their dedifferentiation,
ER stress, and-cell dysfunction. As a consequence of exposure
to increased levels of IGF2, islets are predisposed to be more
sensitive to immune- and nonimmune-mediated -cell dam-
age, triggering the onset of diabetes.
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